Introduction
Chromosome 11q has been identi®ed as a region frequently deleted in haematological and solid cancers. From the results of multiple analyses, it is apparent that subchromosomal interstitial deletions of chromosome 11q predominate, and a few regions of deletion common to multiple tumour types can be identi®ed, in addition to other deleted regions speci®c to particular malignancies (reviewed in Koreth et al., 1998) . Transfer of chromosome 11 (and isochromosome 11q in some cases) has suppressed tumorigenicity of a variety of malignant cell lines, providing functional evidence for tumour suppressor gene(s) on chromosome 11, localized to the q arm in some instances. However, the gene(s) involved have not been identi®ed to date.
Allelic loss at chromosome 11q22-q23.1 has been reported in nonfamilial cancers of the breast (Carter et al., 1994 ; Koreth et al., 1995 Koreth et al., , 1997 Negrini et al., 1995; Winqvist et al., 1995) , ovary (Davis et al., 1996; Foulkes et al., 1993; Gabra et al., 1995 Gabra et al., , 1996 , cervix , skin (Herbst et al., 1995) , stomach (Baa et al., 1996) , lung (Iizuka et al., 1995; Rasio et al., 1995) , bladder (Shaw and Knowles, 1995) and possibly colon (Keldysh et al., 1993; Koreth et al., 1997; Tomlinson and Bodmer, 1996) , in addition to haematological malignancies (B-cell leukaemia) (Dohner et al., 1997; Stilgenbauer et al., 1996) . The consensus region of deletion between the markers D11S2000 and D11S897 (Koreth et al., 1998) contains a number of candidate tumour suppressor genes, including ATM (AT-mutated) and possibly the DDX10 gene (James et al., 1994; Savitsky et al., 1996) . To date, evidence for the involvement of ATM in many of these sporadic malignancies is equivocal (discussed further below) and the role of DDX10 in malignancy is speculative (Laake et al., 1997) , indicating that further investigation is required to localize the putative tumour suppressor at 11q22-q23.1.
In addition, we had recently identi®ed a *2 Mb region of allelic deletion at chromosome 11q25-qter, lost in *50% of the sporadic breast cancer cases analysed (Koreth et al., 1997) . This data indicates another putative tumour suppressor at 11q25-qter, possibly speci®c to sporadic breast cancer. No candidate genes have been identi®ed for this novel locus.
Functional analysis of these two regions on distal 11q was performed by accessing an STS mapped 11q YAC contig (James, unpublished data) and selecting YACs localizing to the ATM locus on 11q23.1 (*1.2 Mb) and most of the *2 Mb 11q25-qter region. Mouse ®brosarcoma A9 cells were transfected with the 11q YACs and transfectant clones were assayed for in vivo tumorigenicity in athymic female Balb c-nu/nu mice. Chromosome 11q YAC transfectants from both regions were signi®cantly suppressed for tumour formation in vivo, indicating the presence of tumour suppressors at 11q23.1 and 11q25. These results provide a functional evidence of tumour suppression at two independent 11q loci and map them to individual YACs, sucient for subsequent positional cloning.
lished data) were selected. y666B11, y756A06 and y801E11 mapped to 11q23.1 and y790G09 and y932C09 mapped to 11q25 (Figure 1 ). At 11q23.1, y756 was found to be non-chimaeric by FISH analysis and stable in yeast (Figure 2 ). It was used for further modi®cation. At 11q25-qter, both y790 and y932 were stable and y790 was non chimaeric (Figure 2 ). Both YACs were used for subsequent modi®cation (though y932 yielded signals on other chromosomes, being the distal most 11q YAC available it was retained for the study).
YAC retro®tting and analysis
On the three YACs (y756, y790, y932) and the alphoid control YAC (a5), the pYAC4 vector right arm was retro®tted with pRAN4 (Markie et al., 1993) , containing the G418 resistance marker`neo'. The yeast transformants were grown under selection and retro®tting was con®rmed by restriction digestion and Southern blotting. Human genomic insert size, assessed by PFGE, was unaltered in the retro®tted clones.
Transfection of A9 cells, clonal selection and analysis
The control alphoid`neo' transformant YAC (a5pRAN) was used to optimize the protocols for spheroplast fusion to the murine A9 cell line (control) and the human cell lines D98/AH-2B and MCF-7 (in both of which tumour suppression by human chromosome 11 had been reported Srivatsan et al., 1986) ). While spheroplast fusion to murine cells was successful, stable YAC transfectants were not obtained with the human cell lines. Therefore, the murine A9 ®brosarcoma cells were used as the recipient cell line for transfection with the 11q YACs. G418 resistant clones were isolated from a minimum of three repeat transfections. Clones with thè neo' gene and both vector arms intact (suggesting insert stability) (data not shown) were expanded and analysed by restriction digest ®ngerprinting with a human Alu repeat probe. Most clones had good identity with the parental YAC (Figure 3) . A yeast repetitive`Ty' element probe showed variable amounts of yeast DNA in the dierent clones, indicating that they represented independent integration events (data not shown). Metaphase spreads showed that YAC DNA had integrated into a mouse chromosomes (Figure 2 ). While in most cases the cells had ā attened ®broblastic morphology, some clones (e.g. A9/y790 clone B) had a multinucleated giant cell morphology, but this did not correlate with in vivo growth. Suitable clones (A9/y756 clones A ± D, A9/ y790 clones A ± D and A9/y932 clones A ± C) were expanded and 1610 6 cells were inoculated subcutaneously into athymic female Balb c-nu/nu mice.
Tumorigenicity assay
In the 5 week in vivo tumorigenicity assay, the control untransfected A9 cells reached a mean weight of 4.3 g ( Table 1 ). The A9/a5 YAC transfectant (a control YAC containing human alphoid DNA insert transfected into earlier passage A9 cells) reached a mean weight of 2.3 g. High passage A9 cells transfected with y756 (11q23.1) were signi®cantly suppressed for in vivo tumorigenicity in all four clones (A ± D) assayed, though the extent of suppression varied among the clones (Figure 4 ), ranging from no tumour formation (A9/y756 clone B) to tumours with a mean weight of 0.85 g (A9/y756 clone C).
Similarly, signi®cant tumour suppression occurred for the high passage A9 cells transfected with the overlapping YACs y790 and y932 (11q25-qter). All seven clones (A9/y790 clones A ± D; A9/y932 clones A ± C) for the 11q25-qter YACs showed signi®cant suppression (Figure 4 ) though the extent of suppression varied between the clones (Table 2) , ranging from a mean weight of 0.02 g (A9/y790 clone C) to 0.86 g (A9/y790 clone B).
Analysis of tumours
Where tumours of sucient size developed at 5 weeks, their DNA band pattern and intensity was compared with the parental subclone and the original 11q YAC. In most cases, Alu repeats were detected in the tumours, though the band pattern was altered in some cases, and the intensity of the bands detected varied considerably, indicating both rearrangement and unequal segregation of the insert DNA. At 11q23.1 (y756), in a simple regression analysis, in vivo tumour suppression correlated signi®cantly with retention of Alu band identity (P=0.015) and the combined measures of band intensity and identity (a crude index of`insert integrity') in the tumour DNA (P=0.022), but not with retention of yeast DNA (P=0.50) (data not shown). Similarly, in a simple regression analysis, in vivo tumour suppression at 11q25-qter also correlated signi®cantly with retention of Alu band identity (P50.0001) as well as band intensity In all cases, histological analysis of formalin ®xed, paran embedded tumour material was performed on routine haematoxylin and eosin stained sections. No phenotypic dierences between the tumours was detected, though some intra-tumour phenotypic heterogeneity was noted within each sample.
Discussion
In this study we have identi®ed two tumour suppressor loci on chromosome 11q by in vivo functional complementation. The proximal locus, at 11q22-q23.1, has been identi®ed as a region frequently deleted in solid and lymphoreticular malignancies, at frequencies ranging from 20 ± 65% (reviewed in Koreth et al., 1998) . The frequency and consistency of the 11q22-q23.1 deletion in B-cell leukaemia, malignant melanoma, breast, cervical, bladder, lung, gastric and ovarian cancer suggests the presence of an important tumour suppressor gene(s) within this region. However, the extent of the region involved has not been suciently ®ne mapped for positional cloning in most tumour types, current deletion maps being in excess of 4 Mb around the critical region, though eorts have been made to narrow the gap (Laake et al., 1997) . Additionally, while transfer of chromosome 11 has been demonstrated functional in vitro (Gioeli et al., 1997) and in vivo tumour suppression in cell lines derived from melanomas (Robertson et al., 1996) , cancer of the breast Phillips et al., 1996) and cervix (Horikawa et al., 1995; Srivatsan et al., 1986) , the eect has not been localized to the 11q22-q23 region (and often not even to chromosome 11q).
Here we demonstrate that the YAC at 11q23.1, y756, when transfected into high passage murine A9 ®brosarcoma cells, signi®cantly suppress in vivo tumour formation. The four clones selected (A ± D), representing independent YAC integration events into the mouse genome, were all suppressed compared to the untransfected A9 cells or an`irrelevant' YAC transfectant. However, it was apparent that among the clones there was appreciable variability in the degree of tumour suppression obtained. This variability was found to correlate signi®cantly with semiquantitative measures of the degree of insert integrity (P=0.022) in the tumours, more so with the band pattern (P=0.015) than intensity (P=0.09). This suggests that both genetic rearrangement (implying These results con®rm the presence of a tumour suppressor locus within the YAC y756 and localize it to an *1.2 Mb genomic region on 11q23.1 between the markers D11S384 and D11S2180. This genomic region contains the genes ACAT and ATM, (James, unpublished data) while the DDX10 gene partially overlaps with the distal end of the YAC (Laake et al., 1997) . While ACAT (Acetyl Choline Acyl Transferase) is not believed to be involved in oncogenesis, the ATM gene is considered a candidate tumour suppressor gene. The A-T syndrome, resulting from mutations in ATM predisposes to a markedly elevated (70 ± 250-fold) cancer risk, primarily lymphoid (Sedgwick and Boder, 1991; Shiloh, 1994) . Heterozygous A-T carriers have been estimated to have a 3 ± 5-fold increased cancer risk (especially breast cancer) (Easton, 1994; Swift et al., 1991) . While the function of the ATM gene product is not fully characterized, based on sequence homology it is thought to have a role in cell cycle checkpoint control (Zakian, 1995) . However, direct analysis of the gene in sporadic malignancies (especially investigated in breast cancer), has failed to show a role for ATM mutations in solid tumour oncogenesis (Athma et al., 1996; FitzGerald et al., 1997; Vorechovsky et al., 1996) , though ®ne mapping by microsatellite LOH indicates deletion close to and within the ATM gene (Laake et al., 1997) . To date, therefore, the role of ATM as the tumour suppressor at 11q22-q23.1 remains to be proven. This study, localizing the critical tumour suppressor locus to the region around ATM, strengthens its candidature, but the possibility remains of another closely linked gene mapping to the y756 insert and being the target of the allelic deletion. In this regard, it is interesting to note that y756 overlaps two of the regions of interstitial deletion at 11q23.1 identi®ed by Laake et al. (1997) at ATM and near DDX10.
At 11q25-qter, we had recently mapped a novel region of LOH, lost in *50% of sporadic breast cancers (Koreth et al., 1997) . Following from that observation, we selected two overlapping YACs, y790 and y932, extending to the distal most extent of the 11q YAC contig library available. They were assayed for in vivo tumour suppression of murine A9 ®brosarcoma cells as above. Both overlapping YACs demonstrated signi®cant in vivo tumour suppression in nude mice compared with the control untransfected A9 or`irrelevant' transfectant cell clones. However, as above, amongst clones there were dierences in the degree of tumour suppression obtained. Like the proximal 11q23.1 YAC, the degree of suppression depended on insert integrity in the tumours, correlating highly signi®cantly with the Alu ®ngerprint pattern and cumulative indices of`insert integrity' (P50.0001). In addition, owing possibly to the larger number of transfectant YAC clones (n=7 versus 4) analysed, band intensity in the tumour DNA also correlated signi®cantly with tumour suppression, though again the eect was an order of magnitude less (P=0.003). Like the proximal locus, this suggests that mutation or loss of the insert gene enables subsequent development of non suppressed clones. The region of overlap T1  T2  T3  T1  T2  T3  T1  T2  T3  T1  T2  T3  T1  T2  T3  T1  T2 between the two YACs, between the markers D11S1061 and D11S1185, could be the critical region containing the susceptibility gene. It is *400 ± 600 kb on PFGE estimation, though correlation with the Radiation Hybrid map position (James et al., 1994) is imprecise, as is often the case, especially at chromosome ends (James, unpublished data) . These results indicate a novel tumour suppressor locus at 11q25-qter, probably in the *400 ± 600 kb region of overlap between the two contiguous YACs. Interestingly, the`irrelevant' A9/a5 YAC transfectant with human alphoid DNA produced tumours smaller than the control untransfected A9 cells (but signi®cantly larger than the 11q YACs). While this could represent a nonspeci®c suppressive eect of yeast or human DNA transfer, that is unlikely. For instance, there was no correlation between the amount of yeast DNA transferred and the degree of tumour suppression observed in the 11q YAC transfectants (P=0.22). Further, the transfer of human genes to murine cells has been shown to result in physiological gene expression (Huxley et al., 1991) and nonspeci®c antiproliferative eects have not been observed in A9 cells transfected by YAC or microcell mediated chromosome transfer protocols (Todd et al., 1996; Killary et al., 1992) . Our data, showing that in vivo tumour suppression correlates more with YAC insert DNA identity than intensity, also argues against a primary non speci®c suppression of A9 cells by human DNA transfer. Since the a5 alphoid YAC was transfected into A9 cells *50 passages earlier and frozen down (while the A9 cells continued to be passaged as positive controls during human cell line transfection attempts), it is more likely that the dierence in tumour size between the two A9 control cell populations re¯ects the`tumorigenic progression' of the malignant A9 cell line through extended passage in vitro, making the later passage A9 derived tumours larger than the alphoid YAC A9 transfectant clone, derived from earlier passage A9 cells. Since the 11q YAC transfectants were derived from later passage A9 cells, the highly tumorigenic untransfected A9 cells probably represent a better control than the alphoid YAC transfectant A9 clone. In any event, regardless of the control cell line chosen as the baseline, statistically signi®cant tumour suppression was observed at the 11q loci assayed.
In summary, we have demonstrated in vivo tumour suppression at two loci on chromosme 11q by YAC functional complementation and de®ned the critical regions at *1.2 Mb on 11q23.1 (spanning the ATM locus) and a novel locus of *400 ± 600 kb on 11q25-qter. The fact that these genes signi®cantly suppress the phenotype of highly malignant murine ®brosarcoma lines suggests a possibly signi®cant role for these genes in carcinogenesis. The reagents are now in place to positionally clone these two tumour suppressor genes.
Materials and methods

11q YAC selection and analysis
YACs mapping to the regions of deletion de®ned on 11q22-q23.1 and 11q25-qter were accessed from a genomic 11q YAC contig library cloned into the pYAC4 vector (ura + , trp + ) and mapped by STS content (James, unpublished data) . Saccharomyces cerevisiae strain AB1380 (ade27, C+) was the host strain for YAC propagation. For the 11q22-q23.1 region (*8 Mb), y756A06 (*1.2 Mb; between the markers y734D08L- T1  T2  T3  T1  T2  T3  T1  T2  T3  T1  T2  T3  T1  T2  T3  T1  T2  T3  T1  T2  T3 3/6 3/6 3/3 4/6 4/6 4/6 6/6 6/6 3/3 4/6 4/6 4/6 6/6 6/6 6/6 3/3 3/3 3/3 6/6 6/6 6/6 Tables 1 and 2 DNA parameters vs tumour size. The insert intensity ratio (actual/theoretical optimum), insert Alu identity pattern ratio (actual/ theoretical optimum) and cumulative insert integrity (actual A+B/theoretical optimum A+B) were calculated for the 11q23/1 (Table 1 ) and 11q25 loci (Table 2) , based on DNA data for the transfected cell lines and the resultant in vivo tumours, where available. The data was used to plot graphs based on a simple regression model between these parameters and ®nal tumour weight. In general the parameters correlated signi®cantly with resultant tumour weight (except between intensity ratio vs weight for the 11q23.1 locus, possibly due to the smaller number of transfectant clones used). There was an order of magnitude dierence between the correlative signi®cance of the insert Alu identity compared to insert intensity, suggesting that mutation or rearrangement of the suppressive insert was an important mechanism for the subsequent outgrowth of tumourigenic clones D11S2180), y666B11 (*660 kb; y11B29L-D11S535) and y801E11 (*1.6 Mb; D11S384-D11S2220) containing the ATM locus at 11q23.1 were selected. Similarly for the 11q25-qter region (*2 Mb), y790G09 (*1.2 Mb; D11S1035-D11S1185) and distal most y932C09 (*2.1 Mb; D11S1061-D11S2098) overlapped each other for *400 ± 600 kb (between the markers D11S1061-D11S1185) and covered most of the mapped 11q25-qter deleted region, except the extreme 11q terminal region where STS markers have not been identi®ed (van Heyningen and Little, 1995) . A control YAC, a5, containing human alphoid DNA in the pYAC4 vector, was also accessed (ZL).
Prior to retro®tting, the YACs were cultured in SC (synthetic complete) yeast media de®cient in uracil and tryptophan. Chromosomal and YAC DNA was embedded in agarose plugs by standard methods (Larin, 1995) and YAC copy number, size and stability were assessed by pulsed ®eld gel electrophoresis (PFGE) and Southern blotting, probed by PCR generated pYAC4 speci®c left and right arm probes (Hirst et al., 1991) , radiolabelled by random priming with a-32 P-dCTP (Ambion DecaPrime II Kit, Ambion Inc, USA). To assess chimaericity, chromosome 11q YAC DNA was biotin-labelled (Gibco-BRL Bionick kit, Life Technologies, UK) and dual colour¯uorescence in situ hybridization (FISH) performed with a digoxigenin-labelled 11p control probe (Oncor) to human metaphase spreads by standard methods, detected by FITC-avidin and Rhodamine-antidigoxigenin (Larin, 1995) .
YAC retro®tting and analysis
Prior to transfection into mammalian cells, the YAC vector pYAC4 was retro®tted with the pRAN4 vector (Markie et al., 1993) containing the selectable mammalian resistance marker`neo' (conferring G418 resistance) by spheroplast transformation, as described elsewhere (Larin, 1995) .
DNA from retro®tted clones was analysed by EcoRI digestion to con®rm the presence of an *1.8 kb band, indicating homologous recombination between pRAN4 and the original pYAC4 arm disrupting the ura + gene (Markie et al., 1993) , and the human genomic insert was sized by PFGE as before.
Cell lines
Murine A9 ®brosarcoma (HPRT 7 ) cell lines at high passage were used for the transfection and tumorigenicity assays. Cells were grown in vitro in DMEM with Glutamax I (Gibco-BRL, Life Technologies Ltd, UK), supplemented with 10% FCS. Human cell lines D-98/AH-2B (HeLa derived cervical cell line) and MCF-7 (breast cell line) were accessed from the ECACC, UK, and ATCC, USA, respectively. They were passaged in EMEM with Glutamax I (Gibco-BRL, Life Technologies Ltd, UK), supplemented with 10% FCS. The cell lines were checked for mycoplasma contamination at monthly intervals by nested PCR (ATCC mycoplasma detection kit) and were mycoplasma free throughout this analysis.
YAC transfection of mammalian cells
Mammalian cells were transfected with retro®tted YACs by spheroplast fusion (Larin, 1995) . Resistant clones (from separate plates), selected with G418 (400 mg/ml), were picked over the subsequent 2 ± 4 weeks, expanded through multiwell plates (96, 24, 6 well) and analysed.
Transfectant analysis
DNA from the transfectant clones was digested with EcoRI, ®lter transferred and hybridized with the`neo' gene and right and left YAC arm probes. In transfectants with the intact`neo' gene and single copy right and left YAC vector arms, human 11q inserts were assayed by restriction digest Alu ®ngerprinting of the transfected cells DNA compared to the parental YACs. Brie¯y, 10 mg transfectant DNA (and 100 ± 150 ng YAC DNA) was digested with HindIII, electrophoresed through 0.7% agarose gels, transferred to nylon and ®lters hybridized to a radiolabelled 2 kb human Alu repeat probe (kind gift of Dr AP Monaco). The degree of identity between the transfectants and the original YAC was scored on a scale of increasing identity from 0 ± 4. Similarly, the intensity of the bands observed was estimated, in increasing order from 0 ± 3. The transfectant clones were also assayed for estimation of the total yeast DNA transferred, by probing with the yeast repetitive`Ty' element, random primed with [a-32 P]dCTP. Finally metaphase spreads from transfectant clones were probed with a biotin labelled human Alu repeat probe (or labelled alphoid repeat probe for the control alphoid YAC) and detected with FITC or Cy-3 labelled avidin to localize the YAC inserts in the mouse chromosomal background.
In vivo tumorigenesis
The transfectant A9/y756/y790/y932 clones, control transfectant A9/a5 and untransfected control A9 cells were inoculated subcutaneously at 1610 6 cells in sterile PBS into female BALB c-nu/nu athymic mice; three animals per clone. After 5 weeks, the animals were euthanized, tumours resected, weighed and measured and portions set aside for DNA extraction and paran embedded for histopathological assessment.
Tumour DNA analysis DNA was extracted from frozen tumours (if available) using the Puregene extraction kit (Flowgen Ltd, UK). Ten mg DNA was digested with HindIII, electrophoresed through 0.7% agarose, transferred to nylon and ®lters hybridized to a human Alu probe random primed with [a- 32 P]dCTP as above. An assessment of band identity and intensity, compared to the parental YAC DNA was also made using the graded scale as above.
Statistical methods
For each clone, descriptive statistics (mean, std error, std deviation) were calculated with the Statview 4.5 application package. Inter-clone analysis was performed by unpaired comparison of means (two tailed) of the two groups, and probability estimates of similarity of the two groups obtained. Semi-quantitative estimates of transfectant DNA band intensity (0 ± 3) and pattern identity (0 ± 4) developed for transfected clones and resultant tumour DNA (compared with parental YAC DNA), and expressed as a ratio of the actual value obtained vs theoretical maximum (Tables 1 and 2 ). The fractional value obtained individually for each parameter and cumulatively for the sum of the parameters was plotted against resultant tumour weight, in a simple regression analysis.
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